9 assets in Kidney Medullary Carcinoma

Therapeutic assets addressing Kidney Medullary Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Atezolizumab Kidney Medullary Carcinoma	National Cancer Institute (NCI)	P2	B (60)
Cabozantinib Kidney Medullary Carcinoma	National Cancer Institute (NCI)	P2	B (60)
Nivolumab Kidney Medullary Carcinoma	National Cancer Institute (NCI)	P2	B (60)
Ipilimumab Kidney Medullary Carcinoma	National Cancer Institute (NCI)	P2	B (59)
Adriamycin Kidney Medullary Carcinoma	M.D. Anderson Cancer Center	P2	CCC (53)
Enfortumab Vedotin (Fully Human Monoclonal Antibody Conjugated To A Cytotoxic Agent Monomethyl Auristatin E (Mmae) Targeting Nectin-4) Kidney Medullary Carcinoma	Giuseppe Procopio	P2	CCC (53)
Pembrolizumab Kidney Medullary Carcinoma	Giuseppe Procopio	P2	CCC (53)
Fludeoxyglucose Kidney Medullary Carcinoma	National Cancer Institute (NCI)	P1/2	CCC (48)
Tiragolumab Kidney Medullary Carcinoma	National Cancer Institute (NCI)	P1/2	CCC (48)